Literature DB >> 19164418

Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci.

David M Livermore1, Shazad Mushtaq, Marina Warner, Neil Woodford.   

Abstract

BACKGROUND: TR-700 is the active moiety of TR-701 (DA-7157), a new oral/intravenous oxazolidinone prodrug. We examined its activity against linezolid-susceptible and -resistant staphylococci and enterococci.
METHODS: MICs were determined by the CLSI agar dilution method.
RESULTS: MICs of TR-700 were tightly clustered around 0.5 mg/L for linezolid-susceptible staphylococci and enterococci compared with 2 mg/L for linezolid. MICs for 52 linezolid-resistant isolates were raised, but only exceeded 4 mg/L for two Enterococcus faecium isolates homozygous for the G2576T 23S rRNA mutation and for one with an unknown mechanism of linezolid resistance.
CONCLUSIONS: TR-700 is 4- to 16-fold more active than linezolid and overcame most linezolid resistance in vitro.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19164418     DOI: 10.1093/jac/dkp002

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  24 in total

1.  Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain.

Authors:  Carmen Betriu; Gracia Morales; Icíar Rodríguez-Avial; Esther Culebras; María Gómez; Fátima López-Fabal; Juan J Picazo
Journal:  Antimicrob Agents Chemother       Date:  2010-02-22       Impact factor: 5.191

2.  Tedizolid phosphate.

Authors:  Dennis J Cada; Kyle Ingram; Danial E Baker
Journal:  Hosp Pharm       Date:  2014-11

3.  Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers.

Authors:  Seth T Housman; J Samuel Pope; John Russomanno; Edward Salerno; Eric Shore; Joseph L Kuti; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2012-02-13       Impact factor: 5.191

4.  In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections.

Authors:  Philippe Prokocimer; Paul Bien; Carisa Deanda; Chris M Pillar; Ken Bartizal
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

5.  Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model.

Authors:  R A Keel; P R Tessier; J L Crandon; D P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

6.  Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations.

Authors:  Jeffrey B Locke; John Finn; Mark Hilgers; Gracia Morales; Shahad Rahawi; Kedar G C; Juan José Picazo; Weonbin Im; Karen Joy Shaw; Jeffrey L Stein
Journal:  Antimicrob Agents Chemother       Date:  2010-09-13       Impact factor: 5.191

Review 7.  New Gram-Positive Agents: the Next Generation of Oxazolidinones and Lipoglycopeptides.

Authors:  Matthew P Crotty; Tamara Krekel; C A Burnham; David J Ritchie
Journal:  J Clin Microbiol       Date:  2016-03-09       Impact factor: 5.948

8.  Pharmacokinetics of Tedizolid in Plasma and Sputum of Adults with Cystic Fibrosis.

Authors:  A Young J Park; Joshua Wang; Jordanna Jayne; Lynn Fukushima; Adupa P Rao; David Z D'Argenio; Paul M Beringer
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

9.  Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700).

Authors:  Jeffrey B Locke; Mark Hilgers; Karen Joy Shaw
Journal:  Antimicrob Agents Chemother       Date:  2009-09-14       Impact factor: 5.191

Review 10.  Clinical Pharmacokinetics and Pharmacodynamics of Oxazolidinones.

Authors:  Claire Roger; Jason A Roberts; Laurent Muller
Journal:  Clin Pharmacokinet       Date:  2018-05       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.